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the PDTAs of the most representative Regions. The analysis investigates the follow-
ing Regional characteristics: establishment of a working group to define the PDTA, 
the gap of criteria for prescribing centers with the AISF guidelines, indication of 
therapeutic scheme for the different kind of patients, budget allocation, character-
istics of the management model and existence of a follow up system. Results: 
The results of the study show that, besides some common characteristics observed 
in all Regions (e. g. the presence of working group and criteria for the eligibility of 
patients and identification of prescribing centers), there is a substantial heteroge-
neity in Regional guidelines, especially regarding budget allocation, management 
model and follow up system. Indeed, if in some Regions like Basilicata and Veneto 
there is a specific budget allocation (respectively € 1,2 ml and € 12 ml in 2014), the 
management model is based on Hub and Spoke system and the follow up mecha-
nism is clearly set up, in other Regions like Lombardy and Liguria the guidelines are 
more vague, detailing only few criteria. These Regional differences are confirmed 
by other two data: the timespan between the market authorization of the Triple 
Therapy for HCV patients and the integration in Regional guidelines (e. g. 17 days 
in Veneto and 147 days in Emilia Romagna) and the number of prescribing centers 
per million inhabitants (6,92 in Basilicata and 1,85 in Veneto). ConClusions: The 
study demonstrate that, with a view to the future novel drugs, a common disease 
management model, including common guidelines and organizational model, is 
essential to avoid regional disparities in HCV therapies access.
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objeCtives: This retrospective study aimed to evaluate the actual chronic hepatitis 
C (CHC) treatment in Japan including interferon (IFN) treatment using Japanese 
claims data provided by Japan Medical Data Center Co., Ltd (JMDC). Methods: 
All claims data for 9,634 patients having a history of diagnosis related to CHC, 
liver cirrhosis (LC), or hepatocellular carcinoma (HCC) among Japanese claims data 
from January 2005 to October 2013 provided by JMDC were analyzed in this study. 
Treatment patterns and costs were evaluated in CHC patients newly diagnosed dur-
ing the study period. Results: 3,546 newly diagnosed CHC patients were included 
in this analysis. The median follow-up period was 21.0 months. The CHC treatment 
including IFN was not implemented in most cases (76.8%) during the follow-up 
period. The rate of IFN treatment was 7.0%. The combination therapy of IFN and 
ribavirin (RBV) was the most frequently used in IFN treatment. Median period of 
first line treatment to the discontinuation was 7.0 months in patients with IFN + 
RBV. The mean annual total cost in CHC patients with IFN, CHC patients without 
IFN with other drugs (e. g. ursodeoxycholic acid), CLC patients were 3.5 million yen 
($35,000), 2.0 million yen ($20,000), 3.1 million yen ($31,000), respectively. The mean 
annual number of outpatient visits in patients with IFN + RBV, patients without 
IFN with other drugs were 56.7 and 37.5 visits, respectively. ConClusions: The 
CHC treatment including IFN was not implemented in most cases despite having 
the CHC diagnosis. Furthermore, IFN treatment completion rate are low. One of the 
main causes of these facts would be adverse effects associated with IFN treatment. 
New drugs with fewer adverse effects are awaited for the future.
musCular-skeletal DIsOrDers – Clinical Outcomes studies
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Mughal F.1, Tencer T.2, Clancy Z.2, Zhang F.2
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objeCtives: The PALACE studies compared the efficacy and safety of apremilast 
(APR) with placebo in patients with active psoriatic arthritis (PsA) despite prior 
conventional disease-modifying antirheumatic drugs and/or biologics. The objective 
was to assess the impact of APR on physical functioning in patients enrolled in the 
PALACE trials. Methods: The pooled analysis included data from PALACE 1-3, three 
52-week, randomized, placebo-controlled studies evaluating APR in subjects with 
active PsA. Patients were randomized (1: 1: 1) to placebo, APR 20 mg BID (APR20), or 
APR 30 mg BID (APR30). Patients with < 20% reduction from baseline in swollen and 
tender joint counts at Week 16 were required to be re-randomized (1: 1) to APR20 or 
APR30 if initially randomized to placebo, or continued their initial APR dose. At Week 
24, all remaining placebo patients were re-randomized to APR20 or APR30. The anal-
ysis reports data from the APR-exposure period (Weeks 0 to 52). Physical function, 
a pre-specified secondary end point, was measured using the Health Assessment 
Questionnaire-Disability Index (HAQ-DI) and the 36-item Short-Form Health Survey 
version 2 Physical Functioning (PF) domain and physical component summary (PCS) 
scores. Results: At Week 16, the observed physical function change from baseline 
was improved with APR20 and APR30 vs. placebo, as measured by the HAQ-DI (-0.17 
[P< 0.001] and -0.23 [P< 0.001] vs. -0.07), PF (2.73 [P< 0.007] and 4.08 [P< 0.001] vs. 1.52), 
and PCS (3.44 [P< 0.002] and 4.46 [P< 0.001] vs. 2.03). At Week 52, among patients who 
were treated with APR continuously, the physical function change from baseline for 
APR20 and APR30 was improved, as measured by the HAQ-DI (-0.30 and -0.33), PF 
(5.55 and 5.53), and PCS (6.37 and 6.23). ConClusions: Patients treated with APR30 
reported improvement in physical function compared with placebo, as measured by 
the HAQ-DI, PF, and PCS. This response was maintained over 52 weeks.
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tion (6-month ER visits and hospitalizations). Comparisons in each of these health-
related topics were made between respondents with IBS-C versus non-FGID, asthma, 
migraine, and RA. Comparisons controlled for age and gender. Results: Prevalence 
of IBS-C was 0.67%, 1.03%, and 0.91% in the US, UK, and France, respectively. Most 
respondents were female (> 65%) and mean age ranged from 47.7 to 49.8 years. In 
each country, mean SF-12 physical (PCS) and mental (MCS) summary scores were 
statistically (p< 0.001) and clinically meaningfully (> = 2.5) lower than the non-FGID 
group. With few exceptions, PCS and MCS scores of IBS-C were significantly (p< 0.05) 
lower than scores for asthma, migraine, and RA. In each country, IBS-C reported 
significantly (p< 0.001) greater absenteeism and worse presenteeism and greater 
overall work productivity loss and daily activity impairment than non-FGID, and 
with few exceptions, worse than asthma, migraine, and RA. Lastly, in each country 
the number of ER and hospital visits was significantly higher (p< 0.01) for IBS-C 
compared to non-FGID and, with few exceptions, higher than asthma, migraine, 
and RA. ConClusions: In the three countries respondents with IBS -C showed 
significant and clinically meaningful deficits in HRQoL and work productivity and 
elevated health care utilization compared with other chronic conditions.
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objeCtives: The purpose of this study was to evalute the safety and effectiveness 
of serial transverse enteroplasty (STEP). Methods: The clinical utility of STEP was 
first reviewed in three textbooks and secondly the safety and the effectiveness of 
the STEP were assessed based on a systematic revew. 575 articles were searched 
using database (KoreaMed, Ovid-MEDLINE, Ovid-EMBASE and Cochrane Library, etc.) 
and eliminated acoording to inclusion/exclusion criteria, duplicate search results. 
Finally, 9 articles (2 cohort studied and 7 case studies) were used. Two evaluators 
performed independently throuout each process. The article’s quality evaluated by 
the SIGN’s tool and the grade of recommendation were selected. Results: A review 
of the textbooks revealed that STEP is conducted on patients with refractory SBS. And 
the advantages of STEP are that it is technically straightforward, can form a uniform 
bowel channel regardless of variable underlying bowel dilation, and can be repeated 
if the bowel subsequently radilated. The safety of STEP was assessed based on pro-
cedure-related complications in 6 articles. The complication rate of STEP was overall 
6.3~25%, bleeding 6.3~12.5%, obstruction 6.3~22%, anastomosis leak 2.3~16.7% and 
stricture 11~20%. The complication rate of the STEP versus the Bianchi LILT was no 
significantly difference. The effectiveness of STEP was assessed based on the enteral 
autonomy and survival rate in 9 articles. There was a trend toward a decreased rate of 
PN after STEP. As a result, the 33~56% patients who underwent STEP were weaned off 
within one year and 83~88% after one year. Survival was 83% with maximum follow-
up of 68 months. ConClusions: The safety of STEP was at an acceptable level as 
complications reported in studies generally occur after an intestinal operations and 
such problems can be corrected surgically. The clinical utility of STEP was described 
in the textbooks as a non-transplantation procedure and all the selected articles 
was reported on wean-off parenteral nutrition. Therefore, there is evidence for the 
safety and effectiveness of STEP performed on patients with refractory short bowel 
syndrome for promoting eneteral nutrition (Recommendation grade C).
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objeCtives: Ulcerative colitis is one of 56 designated diseases for the Specified 
Disease Treatment Research Program that provides co-payment reduction or exemp-
tion according to disease severity and patients’ income levels. Under the fee-for-service 
payment system, such financial assistance program may influence drug utilisa-
tion. The objective of this study is to assess the overall drug prescribing pattern for 
ulcerative colitis. Methods: Claims data with indication for ulcerative colitis were 
extracted from the Social Health Insurance claims data processed from December 2009 
to February 2010 and from February to April 2011. Extracted data were analysed and 
compared in terms of patients’ age, types of public subsidy, prescribed places (clinic/
hospital or pharmacy) and pharmacologic classes. Results: Total numbers of patients 
were 67,480 for the former duration and 84,450 for the latter duration. Among them, 
patients who were entitled to the Specified Disease Treatment Research Programme 
were 47,103 and 60,231 respectively. The most commonly used drug was mesalazine 
which accounted for 56% and 59%. Infliximab was prescribed mainly for those entitled 
to the Specified Disease Treatment Research Program. Of total infliximab dose, 23 % 
and 30% were with steroid and 33% and 38% were with mesalazine. Generic utilisa-
tion rate for patients entitled to the Specified Disease Treatment Research Programme 
or other financial assistance programs was low. ConClusions: The highest utiliza-
tion of infliximab and low generic utilization were observed for patients entitled to 
the Specified Disease Treatment Research Programme. Prescribing pattern of drugs 
suggested that some cases did not follow clinical guidelines. Adherence to clinical 
guideline recommendations should be promoted.
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ImPaCt Of reGIOnalIzatIOn In treatments anD GuIDelInes
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objeCtives: The aim of this study is to describe the differences in Patients 
Diagnostic Therapeutic Pathways (PDTA) among Italian Regions, as the Italian sce-
nario shows substantial differences in terms of Regional guidelines, organization 
and allocated budget. Methods: The Regional policies were examined analyzing 
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vs. 7% (range: 0% (Germany/Spain) -25% (UK)). Latest disease severity measures 
documented were (adalimumab vs. etanercept): Swollen Joint Counts: 1.6 (range: 
0.4 (Spain) -2.9 (UK)) vs. 2.7 (1.4 (Germany) -8.0 (UK)), Tender Joint Counts: 2.4 
(range: 0.9 (Spain) -3.5 (Italy)) vs. 4.1 (range: 1.9 (Germany) -9.8 (UK)), and HAQ 
rating: 1.2 (range: 0.4 (Spain) -2.7 (Germany)) vs. 1.5 (range: 1.3 (Germany) -2.0 
(France)). ConClusions: Among PsA patients receiving adalimumab or etaner-
cept monotherapy, disease severity differed within the EU5, with patients on 
etanercept, and patients in Italy and UK, having relatively higher burden and 
poorer outcomes. Factors influencing the observed patterns of geographic varia-
tion and the impact of specific biologic treatments on observed patterns warrant 
further scrutiny to optimize therapeutic interventions and improve outcomes.
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relatIve effICaCy anD safety Of ustekInumab COmPareD tO  
antI-tnf-alfa theraPIes In PatIents WIth aCtIve PsOrIatIC arthrItIs
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National Institute for Quality- and Organizational Development in Healthcare and Medicines, 
Budapest, Hungary
objeCtives: Assess the relative efficacy and safety of ustekinumab compared 
to reimbursed anti-TNF-alfa therapies in patients with active psoriatic arthritis 
(PsA). Methods: Randomized, placebo-controlled, at least 24-week-long, pivotal 
studies were searched in PubMed and EMBASE databases. Patients, participating 
in these trials, had active psoriatic arthritis. They were treated with DMARD and/
or NSAID therapies and had not received any biological treatment before. Meta-
analysis was based on ACR20, ACR50, ACR70, PASI75, HAQ-DI, AE and SAE endpoints. 
The quality assessment of evidences was based on EUnetHTA guidelines. For the 
applicability evaluation Aetkin’s method was used, while the meta-analysis used 
Frequentist approach. The mean and the 95% confidence interval of odd ratios (OR) 
were estimated with the Mantel-Haenszel test and with the fixed effect method. 
Statistical heterogeneity was tested using the Chi-squared-test, publication bias 
was checked with funnel plot. Results: During the literature search 8 studies were 
identified. One study was excluded from the evaluation due to inadequate treatment 
dose. Due to altering placebo arm treatment and a high risk of bias at study level, two 
studies were involved in sensitivity analyses. Anti-TNF-alfa treatments had signifi-
cantly better results on primary and accentuated secondary endpoints (ACR20 week 
24 - ustekinumab vs. placebo: OR= 2,56 (95%CI= 1,74; 3,74); anti-TNF-alfa vs. placebo: 
OR= 7,89 (95%CI= 5,65; 11,1); ACR50 week 24 – ustekinumab vs. placebo: OR= 3,46 
(95%CI= 1,94; 6,17); anti-TNF-alfa vs. placebo: OR= 14,21 (95%CI= 8,01; 25,23)). On the 
other secondary endpoints the differences were not significant, however results 
have shown subservient tendency for anti-TNF-alfa treatment against ustekinumab. 
During the safety comparisons we did not find a substantial difference between 
these treatments. ConClusions: Based on our evaluation the anti-TNF-alfa treat-
ment appears more effective than ustekinumab in the first line biologic treatment 
of psoriatic arthritis.
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PatIents WIth rheumatOID arthrItIs
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objeCtives: To prevent irreversible joint damage in rheumatoid arthritis (RA), bio-
logical drugs have been developed; when insufficient response is observed, the ini-
tial dosage could be increased (dose escalation). The aim of the study was to assess 
dose escalation among different therapeutic strategies and associated health care 
resources use. Methods: An observational retrospective cohort analysis based 
on 3 Local Health Units administrative databases was conducted. Patients who 
filled at least one prescription for biologic agents with a diagnosis of RA between 
01/01/2009-31/12/2011 (enrolment period) were included. Patients were followed-
up for 12 months and characterized on the basis of the previous 12 months. Dose 
escalation and cost of illness were calculated on naïve patients (patients with no 
prior prescriptions of the index biologic); dose escalation was defined as having ≥ 2 
consecutive claims with an average weekly dose 130% greater than the initial aver-
age weekly dose. Results: 594 patients were analyzed, female: male ratio= 3: 1, age 
54±14. Biologic at index date were Etanercept (39%), Adalimumab (25%), Infliximab 
(14%), Abatacept (10%), Tocilizumab (9%), Golimumab (3%). Naïve patients to index 
biologic were 293 (49%); among them, dose escalation was observed in 21.4% 
patients on Infliximab, 11.5% Adalimumab, 5.6% Abatacept, 4.0% Tocilizumab, 3.8% 
Etanercept. Hospitalized patients with RA as main discharge diagnosis were 9.6% 
Infliximab, 6.7% Golimumab, 6.6% Adalimumab, 2.9% Tocilizumab, 2.8% Etanercept, 
2.4% Abatacept. Overall, 95% of cost of illness was driven by biologics, 2% tradi-
tional DMARDs, 3% non pharmacological costs; annual cost of illness was € 13,622 
for Golimumab, € 12,803 Adalimumab, € 11,924 Etanercept, € 11,830 Tocilizumab, 
€ 11,201 Infliximab, € 10,943 Abatacept. Dose escalation was associated with a higher 
expenditure for biologic (€ 12,248 VS € 11,232, p= 0.023) and no difference on other 
costs (€ 464 VS € 566, p= 0.349). ConClusions: Among patients with RA, Abatacept 
was associated to a lower cost of illness and hospitalization ratio, due to a low dose 
escalation rate.
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objeCtives: Recently biological agents with a mechanism of action targeting the 
pathogenesis of rheumatoid arthritis (RA) have emerged as an important treatment. 
Especially, as anti-TNF (anti-tumor necrosis factor antagonist) drugs are effective 
objeCtives: The Work Limitations Questionnaire (WLQ) measures the degree to 
which employed individuals are experiencing health-related limitations at work, 
as well as health-related productivity loss. The PALACE 1 study compared the 
efficacy and safety of apremilast (APR) with placebo in patients with active pso-
riatic arthritis (PsA) despite prior or concurrent conventional disease-modifying 
antirheumatic drugs (DMARDs) and/or prior biologics. The objective of the current 
analysis was to assess the effect of APR on the work productivity of employed 
patients in PALACE 1. Methods: Patients were randomized (1: 1: 1) to receive 
placebo, APR 20 mg BID (APR20), or APR 30 mg BID (APR30). Treatment efficacy 
was assessed at Week 16 based on the intent-to-treat population. Employed 
patients completed the WLQ at baseline and Week 16. Work limitations were cat-
egorized into 4 domains, which were then used to calculate the WLQ index: physi-
cal demands (PDS), mental demands (MDS), time management demands (TMS), 
and output demands (ODS). Improvement in the WLQ index, and its 4 domains, 
is represented by a negative change from baseline. Improvement in work pro-
ductivity is represented by a positive improvement in percentage of productivity 
loss. Results: 504 patients were randomized (mean age: 50.4 years; male: 49.4%). 
Of these, 261 who were employed and completed at least 1 component of the 
WLQ were analyzed. At Week 16, APR20 and APR30, vs. placebo, were associated 
with a greater mean change from baseline in PDS (-5.58 and -6.24 vs. -2.14), MDS 
(-2.22 and -5.18 vs. 1.15), TMS (-4.03 and -8.76 vs. -4.25), and ODS (-5.92 and -10.3 
vs. -1.34), resulting in a greater mean improvement in the WLQ index (-0.01 and 
-0.03 vs. 0.00), which corresponds to a higher median percent improvement of 
productivity loss (18.9% and 24.7% vs. -3.7%). ConClusions: APR20 and APR30 
increased work productivity among patients with active PsA.
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netWOrk meta-analysIs WIth baselIne rIsk aDJustment tO assess 
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objeCtives: To compare the relative efficacy of ustekinumab to alternative thera-
pies in anti-TNF treatment-naïve adult patients with active PsA, while adjusting 
for the variability in placebo response rates across trials. Methods: A Bayesian 
network meta-analysis (NMA) was performed to compare ustekinumab with 
adalimumab, golimumab, etanercept, certolizumab pegol and infliximab. Four out-
comes (PASI75, PASI90, PSARC, ACR20) were analysed after 12-16 and 24 weeks. 
The NMA was conducted using a meta-regression model, with the trial-specific 
estimated baseline risk included as a covariate (Dias et al., 2013). A sceptical prior 
was used for this covariate. Both fixed (FE) and random effects models were con-
sidered. Results: Nine placebo-controlled trials were identified for inclusion in 
the NMA based on systematic literature review, including 2 ustekinumab trials. The 
placebo response rates varied significantly across trials, with ustekinumab trials 
having generally higher values. The median value of the meta-regression coefficient 
ranged between -0.02 and -1.69 (P [coef< 0] between 50% and 95%) over the different 
scenarios and models, suggesting an interaction effect between baseline risk and 
treatment effects. At week 24 using the FE, the probability for ustekinumab 45mg 
and 90mg to be more effective than the comparators based on the PASI75 ranged 
from 87% (etanercept) to 46% (golimumab 100mg) and from 88% (etanercept) to 50% 
(golimumab 100mg), respectively. The variability around the point estimates was 
however large. ConClusions: This analysis indicates baseline risk in PsA-trials 
to be a treatment effect modifier. Any NMA not correcting for baseline risk might 
generate biased results. After adjusting for differences in baseline risk between the 
trials, ustekinumab indicates comparable efficacy to alternative therapies, however 
with high uncertainty around the point estimates.
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objeCtives: To compare the disease status and outcomes of patients with PsA 
receiving adalimumab and etanercept monotherapy in Europe. Methods: A 
multi-country, multi-center medical chart-review study of AS patients was con-
ducted among rheumatologists in UK/France/Germany/Italy/Spain to collect de-
identified data on patients who were recently treated with a biologic as part of 
usual care. Physicians were screened for duration of practice (3-30yrs) and patient 
volume (incl. > 5PsA biologic patients/month) and recruited from a large panel to 
be geographically representative in each country. Eligible patient charts (≥ 3) were 
randomly selected from a sample of prospective patients visiting each center/prac-
tice during the screening period. Physicians abstracted patient diagnosis, treat-
ment patterns/dynamics and patient symptomatology/disease status/outcomes. 
Patients on adalimumab/etanercept monotherapy were analyzed. Results: 249 
eligible PsA patient charts were abstracted; 120 on adalimumab (male: 58%, age: 
46.2yrs, average months on adalimumab: 23.9, 95% on first biologic) and 81 on 
etanercept (male: 51%, age: 47.6yrs, average months on etanercept: 22.7, 94% on 
first biologic). Top-3 comorbidites (adalimumab vs. etanercept) were obesity: 12% 
(range: 4% (France) -20% (Germany)) vs. 9% (range: 0% (France) -25% (UK)), dyslipi-
demia: 8% (range: 0% (Italy) -13% (UK)) vs. 16% (range: 0% (UK) -24% (Italy)) and 
anxiety/depression: 12% (range: 7% (UK) -22% (France)) vs. 6% (range: 0% (UK) -12% 
(Spain)). Among patients with available data, latest lab measures documented were 
(adalimumab vs. etanercept): ESR: 19.2mm/h (range: 16.0 (France) -23.6 (Italy)) vs. 
22.0mm/h (range: 13.0 (Germany) -30.1 (Italy)), CRP: 6.5mg/dl (range: 1.3 (Spain) 
-10.8 (UK)) vs. 13.7mg/dl (range: 6.7 (Germany) -24.0 (UK)), rheumatoid factor-
positive: 10% (range: 0% (UK/Spain) -19% (Germany)) vs. 17% (range: 7% (Spain) 
-50% (UK)), and anti-CPP-positive: 5% (range: 0% (France/Italy/Spain) -50% (UK)) 
